Bile is an alkaline fluid present in the human body which helps in digestion. It contains bile acid which is necessary to absorb fats and fat soluble vitamins in the small intestine. Bile acid sequestrants are a group of resins (ion exchange polymers) used to bind components of bile in the gastrointestinal tract. Bile acid sequestrant disrupts the enterohepatic circulation of bile acid by combining with bile components and preventing reabsorption from gut by increasing the excretion of bile acid in the stool. Bile acid sequestrant effectively helps in reducing plasma low-density lipoprotein cholesterol level, thereby reducing cardiovascular events. Hence, bile acid sequestrant is also called hypolipidemic agent. Bile acid sequestrants are generally used as second line of therapy or additive agents to treat hypercholesterolemia.
Based on drug class, the global bile acid sequestrant drugs market can be segmented into cholestyramine, colestipol, and colesevelam. The colesevelam segment is likely to expand at a significant pace during the forecast period. Colesevelam has greater bile acid binding capacity and affinity at lower doses. Moreover, colesevelam in combination with sulfonylurea, metformin, or insulin is an effective drug for type 2 diabetes patients. This is expected to boost the segment during the forecast period. In terms of distribution channel, the global market can be divided into hospital pharmacies, medical stores, and others. The hospital pharmacies segment is anticipated to expand at a rapid pace during the forecast period, as patients are required to visit hospitals for routine checkup during the treatment, and they find it convenient to buy drugs from hospital pharmacies.
Rise in prevalence of cardiovascular diseases due to high cholesterol level in the developed and developing countries is a major factor fueling the global bile acid sequestrant drugs market. However, bile acid sequestrants drugs reduce the absorption of vitamin A, D, E, and K. Long-term use of this drug could cause deficiency of vitamin A, D, E, and K. in the body. This is anticipated to hamper the market in the next few years.
In terms of region, the global bile acid sequestrant drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market. The region is projected to account for significant share of the global market during the forecast period, due to rise in prevalence of heart disorders because of unhealthy lifestyle trends. Moreover, according to the American Heart Association report 2015, about 85.6 million people suffered from cardiovascular diseases. Rise in geriatric population and increase in awareness about the effect of high cholesterol in the body drive the bile acid sequestrant drugs market in Europe. Rise in the number of diabetic patients, intake of junk food in developing countries such as China and Japan, and advancement in health care facilities are likely to fuel the bile acid sequestrant drugs market in Asia Pacific during the forecast period. Advancement in tests and diagnosis, increase in per capita income, and availability of drugs to treat high cholesterol level are projected to augment the bile acid sequestrant drugs market in Middle East & Africa during the forecast period.
Key players operating in the global bile acid sequestrant drugs market are Endo Pharmaceuticals, Inc., Daiichi Sankyo Company Limited, Pfizer, Inc., Upsher-Smith Laboratories, LLC, and Sandoz, Inc., among others.
No comments:
Post a Comment